Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2026-05-17 Director's Dealing
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Initial Director's Interest Notice x 2 4 pages 154.4KB
Director's Dealing Classification · 95% confidence The document is an ASX Appendix 3X ‘Initial Director’s Interest Notice’ under listing rule 3.19A.1, disclosing directors’ relevant interests in securities (personal share and option holdings). This is a standard insider trading/ director’s dealings notice. It matches the category for Director's Dealing (Code: DIRS).
2026-05-17 English
424B3
Prospectus
2026-05-15 English
Quarterly Results Announcement and SEC Form 10-Q 51 pages 781.8KB
Interim / Quarterly Report Classification · 97% confidence The document is a full SEC Form 10-Q quarterly report for the period ended March 31, 2026, including financial statements, MD&A, risk factors, and other comprehensive unaudited data. It is not merely an announcement or link to a report but contains the report itself. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-12 English
Results for the First Quarter of 2026 3 pages 179.5KB
Earnings Release Classification · 93% confidence The document is a press release titled “Anteris Announces Results for the First Quarter of 2026,” reporting top-line financial metrics (cash outflows, R&D spend, trial updates) for the quarter ended March 31, 2026, and providing a corporate update. It references the detailed Form 10-Q filing for full financials, but itself only provides summary results. This matches the definition of an Earnings Release (initial announcement of quarterly financial results). Q1 2026
2026-05-12 English
Board Appointments 3 pages 217.5KB
Board/Management Information Classification · 89% confidence The document announces the appointment of two individuals to the Board of Directors, detailing their terms, committee assignments, and indemnification agreements. This is a corporate announcement of changes in senior management/governance personnel, fitting the Board/Management Information category.
2026-05-12 English
First US Patients Treated in Global Pivotal PARADIGM Trial 2 pages 178.4KB
Regulatory Filings
2026-05-05 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.